Knowledge HQ

This study introduces Cas9-CLIPT, a method to efficiently integrate large transgenes (2-6 kb) into human T cells without restriction enzymes. It produces highly potent GD2 TRAC-CAR T cells with an enriched stem cell memory phenotype. G-Rex® 6M well plates are referenced for cell cultivation post-electroporation.

This study identifies PRDM1 as a key regulator of NKT cell central memory and effector function using CRISPR screening. PRDM1 knockdown preserved cytotoxicity and memory phenotype. NKT cells were expanded and restimulated in 6-well G-Rex® plates during the protocol.

This poster describes a simplified CAR-T manufacturing method (Spo-T) using RetroNectin-coated G-Rex® vessels. This approach allows simultaneous T-cell activation and transduction in a single vessel, showing higher proliferation and stemness compared to conventional methods.

This study identifies CSF1R+ myeloid-monocytic (LAMM) cells as drivers of CAR-T resistance in B-NHL. CSF1R inhibition combined with CAR-T therapy enhanced efficacy. Author H. Balke-Want received funding from the G-Rex® Grant Program (Wilson Wolf), though specific device usage for main data is not detailed.

This study develops CD38KO/CD38-CAR γδT cells to treat T-cell malignancies, avoiding fratricide. A hybrid expansion protocol using G-Rex® plates allowed robust expansion of polyclonal γδT cells. The edited cells showed potent anti-tumor activity in vitro and in vivo against T-ALL.

This study describes T cells engineered with five genes (WT1-TCR, NFAT-GMCAR, CD33 BiTE, tEGFR) to target AML. G-Rex® plates were used for co-culture assays with primary AML cells and bone marrow to evaluate cytotoxicity and safety. The strategy enhances anti-tumor potency and provides a safety switch.

This presentation details the process development (V2.0) for nula-cel, a gene-edited HSPC product for Sickle Cell Disease. G-Rex® were implemented for cell culture, improving cell health and scalability compared to the V1.0 process. The optimized process showed improved engraftment and editing efficiency.

This study optimizes isolation, CRISPR-Cas9 knockout of SRC-3, and expansion of human regulatory T cells (Tregs) for adoptive cell therapy in solid tumors. Using G-Rex® bioreactors, they achieved a 25-to-40-fold expansion rate, maintaining high FOXP3 expression and viability.

The study investigates the toxicity of CD147-CAR-NK therapy in a human CD147 transgenic mouse model. NK cells were expanded and transduced in G-Rex® plates. Results indicate minimal on-target/off-tumor toxicities and less neuroinflammation compared to CAR-T therapy, supporting clinical potential.

This paper describes a knock-in strategy (KI-Ep) inserting a constitutive expression cassette into the CX3CR1 locus of HSPCs to regulate transgene expression. G-Rex® systems were used for the long-term culture of edited HSPCs. The method enables low expression in stem cells and activation upon myeloid differentiation.

This study optimizes non-viral Sleeping Beauty CAR-CIK cell production. Switching from T-flasks to G-Rex® reduced handling time and produced less differentiated cells with enhanced metabolic fitness and in vivo efficacy. The method was validated in GMP conditions for clinical scalability.

This study evaluates a fully enclosed CAR-T manufacturing process eliminating biosafety cabinets. It uses CellSeal Connect vials for cryopreservation and G-Rex® for cell activation and expansion. Results show comparable cell expansion, viability, and transduction to standard open processes.